Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
AffiliationNational Children's Hospital, Tallaght, Dublin, Ireland. Peter.Greally@amnch.ie
Drug Resistance, Bacterial
Respiratory Tract Infections
MetadataShow full item record
CitationChallenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis. 2012, 28 (6):1059-67 Curr Med Res Opin
PublisherCurrent medical research and opinion
JournalCurrent medical research and opinion
AbstractPseudomonas aeruginosa (Pa) is the predominant pathogen infecting the airways of patients with cystic fibrosis (CF). Initial colonization is usually transient and associated with non-mucoid strains, which can be eradicated if identified early. This strategy can prevent, or at least delay, chronic Pa infection, which eventually develops in the majority of patients by their late teens or early adulthood. This article discusses the management and latest treatment developments of Pa lung infection in patients with CF, with a focus on nebulized antibiotic therapy.
- Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden.
- Authors: Knudsen PK, Olesen HV, Høiby N, Johannesson M, Karpati F, Laerum BN, Meyer P, Pressler T, Lindblad A, Scandinavian CF Study Consortium (SCFSC).
- Issue date: 2009 Mar
- Value of inhaled antibiotics in cystic fibrosis patients.
- Authors: Wunderlich P, Paul KD, Wehner J
- Issue date: 1990
- Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
- Authors: Hansen CR, Pressler T, Høiby N
- Issue date: 2008 Nov
- Managing Pseudomonas aeruginosa respiratory infections in cystic fibrosis.
- Authors: Langan KM, Kotsimbos T, Peleg AY
- Issue date: 2015 Dec